Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyHealth Net Dupilumab Coverage & Prior Auth Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedHealth NetPolicy CP.CPA.360

    Dupilumab (Dupixent) coverage and medical necessity criteria

    Customize your policy alerts

    Sign up for Health Net Policy CP.CPA.360 alerts

    Get alerted when Policy CP.CPA.360 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical necessity, prior authorization, dosing limits, and continuation criteria for dupilumab (Dupixent) for multiple FDA‑approved and selected off‑label indications for Health Net commercial lines of business in NC.

    Policy Summary
    PayerHealth Net
    PolicyDupilumab (Dupixent) coverage and medical necessity criteria
    Policy CodePolicy CP.CPA.360
    Change TypeAdded indicationsrevised COPD FEV1 threshold
    Effective DateMar 1, 2025
    Next Review DateN/A
    Key ActionPrior authorization required; submit documentation showing member meets indication-specific criteria including diagnosis confirmation, prior therapy failures, age/weight, dosing limits, and absence of concurrent biologic or JAK inhibitor therapy.
    SourceLink
    POLICY UPDATE CHANGES

    For COPD, revised post-bronchodilator FEV1 requirement from 30-70% to 20-80% to align with Nucala.

    Added new indication for chronic spontaneous urticaria (CSU) per updated prescribing information.

    Added new indication for bullous pemphigoid (BP) per updated prescribing information and P&T-approved clinical guidance.

    3new or revised indications referenced in RT4 notes
    ProhibitedConcurrent biologics
    6 monthsApproval duration
    Weight-basedPediatric dosing bands
    MultipleIndications addressed

    Medical Necessity and Coverage Criteria

    Initial Therapy — Atopic Dermatitis initial approval criteria

    Covered when ALL of the following are met

    Atopic Dermatitis initial: Diagnosis of atopic dermatitis affecting either: (a) ≥10% body surface area OR (b) involvement of hands, feet, face, neck, scalp, genitals/groin, and/or intertriginous areas; AND prescribed by or in consultation with a dermatologist, allergist, or immunologist; AND age ≥ 6 months; AND failure of one non‑steroidal topical therapy used for ≥4 weeks (e.g., tacrolimus 0.03% ointment, pimecrolimus 1% cream) AND failure of one formulary medium to very high potency topical corticosteroid used for ≥2 weeks; AND not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; AND dose does not exceed the indication‑specific age/weight dosing limitssee dosing nodes

    Initial and maintenance dosing stratified by age and weight provided in policy

    Initial Therapy — Asthma initial approval criteria

    Covered when ALL of the following are met

    Asthma initial:
    Policy Summary
    PayerHealth Net
    PolicyDupilumab (Dupixent) coverage and medical necessity criteria
    Policy CodePolicy CP.CPA.360
    Change TypeAdded indicationsrevised COPD FEV1 threshold
    Effective DateMar 1, 2025
    Next Review DateN/A
    Key ActionPrior authorization required; submit documentation showing member meets indication-specific criteria including diagnosis confirmation, prior therapy failures, age/weight, dosing limits, and absence of concurrent biologic or JAK inhibitor therapy.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Billing ImplicationsPrior Authorization, Documentation, and Operational RequirementsBackground and Clinical ContextClinical Definitions and Diagnostic ThresholdsPolicy Update History
    Diagnosis of asthma AND either blood eosinophils ≥150 cells/mcL within the past 3 months OR currently receiving maintenance systemic glucocorticoids for ≥4 weeks; AND prescribed by or in consultation with an allergist, immunologist, or pulmonologist; AND age ≥6 years; AND member has experienced ≥2 exacerbations in past 12 months despite adherence to controller therapy (medium‑ to high‑dose ICS plus LABA or LTRA if LABA contraindicated) OR an urgent care/ER visit or hospital admission; AND dupilumab is prescribed concurrently with ICS plus either LABA or LTRA; AND not prescribed concurrently with another biologic immunomodulator or JAK inhibitor; AND dose does not exceed indication‑specific limits.
    Asthma dosing: Initial one‑time dose for age >12 years: 600 mg; maintenance and pediatric weight/age dosing specified in policy.

    Initial Therapy — CRSwNP initial approval criteria

    Covered when ALL of the following are met

    CRSwNP initial: Diagnosis of chronic rhinosinusitis with nasal polyps with documented nasal polyps and bilateral disease with signs/symptoms ≥12 weeks; prescribed by or in consultation with an allergist, immunologist, or otolaryngologist; age ≥12 years; required systemic corticosteroids for symptom control within last 2 years unless contraindicated; failure of maintenance therapy with ≥2 intranasal corticosteroids (one must be Xhance in adults), each used ≥4 weeks unless contraindicated; dupilumab prescribed concurrently with an intranasal corticosteroid unless contraindicated; not prescribed concurrently with another biologic immunomodulator; dose ≤300 mg every other week.

    Initial Therapy — Eosinophilic Esophagitis (EoE) initial approval criteria

    Covered when ALL of the following are met

    EoE initial: Diagnosis of eosinophilic esophagitis confirmed by ≥15 eosinophils per high‑power field on endoscopic biopsy; prescribed by or in consultation with an allergist, immunologist, or gastroenterologist; age ≥1 year and weight ≥15 kg; absence of hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis; failure of one of the following unless contraindicated: proton pump inhibitor or corticosteroid; not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; dosing limits per weight categories apply (see dosing); approval duration 6 months.
    EoE dosing summary: Weight 15 to <30 kg: 200 mg every other week; Weight 30 to <40 kg: 300 mg every other week; Weight ≥40 kg: 300 mg every week.

    Initial Therapy — Prurigo Nodularis initial approval criteria

    Covered when ALL of the following are met

    PN initial: Diagnosis of prurigo nodularis with documentation including a numeric rating scale ≥7 (0–10) and ≥20 nodular lesions total across specified body areas; prescribed by or in consultation with a dermatologist; age ≥18 years; failure of a ≥2‑week course of a medium to very high potency topical corticosteroid unless contraindicated; not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; initial one‑time dose 600 mg, maintenance 300 mg every other week; approval duration 6 months.

    Initial Therapy — COPD with eosinophilic phenotype initial approval criteria

    Covered when ALL of the following are met

    COPD initial: Diagnosis of COPD with post‑bronchodilator FEV1/FVC <0.7 and post‑bronchodilator FEV1 ≥20% and <80% predicted; documentation of eosinophilic phenotype with blood eosinophils ≥300 cells/µL; history of ≥2 moderate or ≥1 severe exacerbations in past 12 months; failure of triple inhaled therapy (LABA+LAMA+ICS) at maximally indicated doses for ≥3 months OR if contraindicated to ICS, failure of dual therapy (LABA+LAMA) for ≥3 months; provider attestation of concomitant maintenance inhaled therapy; not prescribed concurrently with another biologic immunomodulator; dose ≤300 mg every other week.

    Initial Therapy — Chronic Spontaneous Urticaria (CSU) initial approval criteria

    Covered when ALL of the following are met

    CSU initial: Diagnosis of chronic spontaneous urticaria; prescribed by or in consultation with a dermatologist, immunologist, or allergist; age ≥12 years; failure of two antihistamines (including one second‑generation) at maximum indicated doses each used ≥2 weeks AND failure of a leukotriene receptor antagonist in combination with an antihistamine at maximum doses for 2 weeks unless contraindicated; not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; dosing and weight/age‑specific initial and maintenance doses specified in policy (e.g., age 12–17 weight 30 to <60 kg: 200 mg Q2W; age ≥18 or weight ≥60 kg: 300 mg Q2W).

    Initial Therapy — Bullous Pemphigoid (BP) initial approval criteria

    Covered when ALL of the following are met

    BP initial: Diagnosis of bullous pemphigoid confirmed histologically, serologically (anti‑BP180 or anti‑BP230 IgG by ELISA), or by immunofluorescence; prescribed by or in consultation with a dermatologist; age ≥18 years; inadequate response to at least one corticosteroid at up to maximally indicated doses unless contraindicated; failure of at least one non‑steroidal immunosuppressive agent at up to maximally indicated doses unless contraindicated; prescribed in combination with a tapering course of oral corticosteroid; not prescribed concurrently with another biologic immunomodulator; initial one‑time dose 600 mg, maintenance 300 mg every other week; approval duration 6 months.

    Initial Therapy (off‑label) — Immunotherapy‑related Pruritus initial approval criteria

    Covered when ALL of the following are met

    Immunotherapy-related pruritus initial: Diagnosis of immune checkpoint inhibitor‑related severe pruritus (G3) or moderate‑to‑severe bullous dermatitis (G2‑G4); prescribed by or in consultation with an oncologist; for severe pruritus, failure of a gabapentinoid after 1 month; for moderate bullous dermatitis, failure of ≥3 days of prednisone/methylprednisolone; prescribed regimen must be FDA‑approved or recommended by NCCN; dosing within FDA maximum or supported by practice guidelines/peer‑reviewed literature with prescriber submission of supporting evidence for doses beyond FDA limits; not prescribed concurrently with listed biologics; approval duration 6 months.

    Continuation Therapy — General continuation criteria applicable across indications

    Covered when ALL of the following are met

    Continuation general: Member is currently receiving medication via Centene benefit or previously met initial approval criteria OR member is in continuity of care scenario; AND member is responding positively to therapy as evidenced by indication‑specific clinical improvement; AND if dose increase requested, new dose does not exceed indication‑specific maximums; AND dupilumab is not prescribed concurrently with another biologic immunomodulator or JAK inhibitor.

    Approval duration typically 6 months or to the member's renewal date, whichever is longer.

    Initial/Continuation — Prurigo Nodularis specific criteria

    Must meet ALL of the following for continuation or initial approval

    PN_All: Member is currently receiving medication via Centene benefit or has previously met initial approval criteria; member meets continuity of care provisions if applicable; member is responding positively to therapy (e.g., improvement in itching or skin pain, reduction in nodules); Dupixent is not prescribed with another biologic immunomodulator or a JAK inhibitor; dose increase requests must not exceed 300 mg every other weekdose <= 300 mg Q2W

    Approval duration: 6 months or to member's renewal date

    Initial/Continuation — COPD specific criteria

    Must meet ALL of the following for continuation or initial approval

    COPD_All: Member is currently receiving medication via Centene benefit or previously met initial approval criteria; continuity of care provisions apply if enrolled in applicable state/product; member is responding positively to therapy; Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; dose increase requests must not exceed 300 mg every other weekdose <= 300 mg Q2W

    Approval duration: 6 months or to member's renewal date

    Initial/Continuation — Chronic Spontaneous Urticaria specific criteria

    Must meet ALL of the following for continuation or initial approval

    CSU_All: Member is currently receiving medication via Centene benefit or previously met initial approval criteria; continuity of care provisions apply if enrolled in applicable state/product; member is responding positively to therapy; Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; dosing limits depend on age/weight (age 12-17 and weight 30 to <60 kg: 200 mg every other week; age ≥18 or weight ≥60 kg: 300 mg every other week)200 mg Q2W for 12-17y 30-<60kg; 300 mg Q2W for >=18 or >=60kg

    Approval duration: 6 months or to member's renewal date

    Initial/Continuation — Bullous Pemphigoid specific criteria

    Must meet ALL of the following for continuation or initial approval

    BP_All: Member is currently receiving medication via Centene benefit or previously met initial approval criteria; continuity of care provisions apply if enrolled in applicable state/product; member is responding positively to therapy; Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; dose increase requests must not exceed 300 mg every other weekdose <= 300 mg Q2W

    Approval duration: 6 months or to member's renewal date

    Initial/Continuation — Immunotherapy‑related Pruritus (Off‑label) specific criteria

    Must meet ALL of the following for continuation or initial approval (off‑label pathway)

    ImmunotherapyPruritus_All: Member is currently receiving Dupixent via Centene benefit or documentation shows at least 30 days of Dupixent for a covered indication; member is responding positively to therapy; if a dose increase is requested, new dose must be within FDA maximum limit for any FDA‑approved indication or be supported by practice guidelines or peer‑reviewed literature with prescriber submission of supporting evidence; prescribed regimen must be FDA‑approved or recommended by NCCNsupporting evidence required for doses beyond FDA limits

    Approval duration: 6 months

    Other Indications / Off‑label pathway

    When the requested diagnosis/indication is not specifically listed, follow one of the pathways below

    Other_Indications: If drug is on formulary/PDL follow no‑coverage criteria policy CP.CPA.190 (commercial) or formulary guidance; if not on formulary follow non‑formulary policy CP.CPA.190; if use not listed and above do not apply refer to off‑label use policy CP.CPA.09refer to specified policies

    Applies when diagnosis/age/dosing not specifically listed

    Label-specified dosing by indication

    Dosing regimens by indication (label-referenced); coverage should align with these regimens and weight bands for pediatric patients.

    Atopic dermatitis (moderate-to-severe): Adults: initial 600 mg SC then 300 mg SC every other week; adolescents 6-17: weight-based regimens — 5 to <15 kg: 200 mg every 4 weeks (6 months–5 years band), 15 to <30 kg: 300 mg every 4 weeks (pediatrics) or for 6–17 years specific bands per label; ≥60 kg: 600 mg initial then 300 mg Q2W; see policy for full pediatric weight bands.weight bands apply

    Chunks 47-48

    Asthma (moderate-to-severe): Adults and adolescents ≥12: either initial 400 mg then 200 mg Q2W or initial 600 mg then 300 mg Q2W; patients requiring maintenance oral corticosteroids or with comorbid moderate‑to‑severe atopic dermatitis should start with 600 mg then 300 mg Q2W; adolescents 6–11 have weight-based regimens as specified in policy.age and weight-based dosing

    Chunk 48

    Chronic rhinosinusitis with nasal polyps (CRSwNP): 300 mg SC every other week.none

    Chunk 48

    Eosinophilic esophagitis (EoE): Adults and pediatric patients ≥1 year: dosing described with maximum dose reference of 300 mg/week per labeling; weight-based regimens apply for pediatric patients.age

    Chunk 48

    Chronic spontaneous urticaria (CSU): Age ≥18: one-time initial 600 mg SC then maintenance 300 mg SC Q2W; age 12–17: weight-based initial and maintenance dosing per label (e.g., weight 30 to <60 kg: initial 400 mg then maintenance 200 mg Q2W; weight ≥60 kg: initial 600 mg then maintenance 300 mg Q2W).age and weight

    Chunk 49

    Prurigo nodularis (PN) and Bullous pemphigoid (BP): PN and BP dosing: initial 600 mg SC then 300 mg SC every other week as specified.none

    Chunk 49

    COPD: Dosing regimen listed as 300 mg SC every other week (per label).none

    Chunk 49

    Policy update summary — RT4 updates and indication additions summary

    Summary of recent material updates and additions

    RT4 updates: RT4 and adaptation notes: added new indications for Chronic Spontaneous Urticaria (CSU) and Bullous Pemphigoid (BP); revised COPD post‑bronchodilator FEV1 requirement to 20–80% to align with another biologic's criteria; these are material policy changes documented in the policy history.

    Refer to policy history for dates and P&T approvals.

    These criteria do not apply to California Exchange Plans. For members covered under California marketplace products, refer to the plan‑specific Dupilumab criteria in HIMPA.SP69 for authorization requirements and coverage determinations.

    Coverage is not authorized for treatment of acute bronchospasm or status asthmaticus. Requests for uses that are not FDA‑approved and not specifically addressed in this policy will not be authorized unless the prescriber provides sufficient documentation of efficacy and safety per the referenced off‑label use policy (CP.CPA.09) or formulary/non‑formulary guidance (CP.CPA.190).

    Known hypersensitivity to Dupixent (dupilumab) or any of its excipients is a contraindication and will result in denial of therapy.

    Listing or omission of procedure, HCPCS, CPT, or NDC codes in this policy is for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage; providers must follow the most current plan‑specific coverage documents and professional coding guidance when submitting claims.

    Requests for indications not listed in the Diagnoses/Indications sections should follow the applicable formulary or non‑formulary policies (CP.CPA.190) or the off‑label use policy (CP.CPA.09) for the member's line of business. Documentation requirements from those policies apply when requesting coverage for unlisted or non‑formulary uses.

    Authorization for off‑label indications requires that the prescriber submit adequate supporting evidence of efficacy and safety as specified by the off‑label policy. Doses or regimens outside FDA labeling must be supported by practice guidelines or peer‑reviewed literature and be consistent with the requirements outlined in CP.CPA.09.

    No explicit statements in this document fragment define additional conditions that are categorically labeled as "not medically necessary." For requests outside the diagnoses and dosing listed, refer to the formulary/no‑coverage and off‑label policies cited elsewhere in this policy for applicability and denial rationale.

    Coding and Billing Implications

    Covered HCPCS/CPT/NDC codes (document references coding implications revision log but specific codes not listed in this section)mixed
    No codes listed
    Coding Implications — referenced codesHCPCS
    C9399Unclassified or biologicals drugs
    J3590Unclassified biologics
    Key lab/diagnostic thresholds — eosinophils and EoE
    Asthma blood eosinophilsAbsolute blood eosinophil count ≥150 cells/mcL within the past 3 months
    COPD blood eosinophilsBlood eosinophil count ≥300 cells/µL to document eosinophilic phenotype
    EoE biopsy thresholdEosinophilic esophagitis confirmed by ≥15 eosinophils per high‑power field (eos/hpf) on endoscopic biopsy
    Dosing by age/weight — pediatric weight bands and summary
    Adult standard regimen (most indications)Initial one‑time dose 600 mg SC then maintenance 300 mg SC every other week (common adult regimen for AD, PN, BP; indication-specific exceptions apply)
    Pediatrics 6–17 years (weight bands for atopic dermatitis)15 to <30 kg: loading 600 mg then 300 mg every 4 weeks; 30 to <60 kg: initial 400 mg then 200 mg every other week; ≥60 kg: 600 mg then 300 mg every other week
    Pediatrics 6–11 years (asthma examples)Age 6–11 years and weight 15 to <30 kg: 300 mg every 4 weeks; age 6–11 years and weight ≥30 kg: 200 mg every other week (per asthma dosing nodes)
    Younger pediatric bands (6 months–5 years for AD)Age 6 months–5 years: weight 5 to <15 kg: 200 mg every 4 weeks; 15 to <30 kg: 300 mg every 4 weeks (see atopic dermatitis dosing details)
    post‑bronchodilator FEV1 threshold for COPD (updated)
    Post‑bronchodilator FEV1 threshold (COPD) — updated rangePost‑bronchodilator FEV1 ≥20% and <80% of predicted (revised from prior 30–70% range)
    FEV1/FVC requirementPostbronchodilator FEV1/FVC < 0.7 required to document airflow obstruction for COPD
    Supporting requirementDocumentation of eosinophilic phenotype (blood eosinophils ≥300 cells/µL) and history of exacerbations required alongside FEV1 criteria

    Prior Authorization, Documentation, and Operational Requirements

    Prior Authorization

    Prior authorization required — document indication‑specific criteria

    Prior authorization is required. The provider must document that the member meets the indication‑specific initial or continuation criteria including prescriber specialty, prior therapy failures, age/weight requirements, dosing limits, and that dupilumab is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor.

    • Provider attestation that member meets all listed approval criteria (diagnosis confirmation, prior treatment failures, age/weight, prescriber specialty).
    • Dose requested does not exceed indication‑specific limits.
    Prior Authorization

    Prior authorization requirements — therapy status, response, and no concurrent biologics/JAK inhibitors

    PA requests must state current therapy status and evidence of clinical response for continuation requests, and confirm the member is not receiving another biologic immunomodulator or a JAK inhibitor. Approvals are typically issued for 6 months or to the member's renewal date.

    • Document current therapy status and positive response to therapy.
    • Confirm absence of concurrent biologic or JAK inhibitor therapy.
    • Note typical approval duration: 6 months or to renewal date.
    Prior Authorization

    PA must include indication and weight‑based dosing for pediatric requests

    For pediatric requests, the prior authorization must specify the exact diagnosis and the patient’s weight and indicate the requested dupilumab regimen consistent with labeled, weight‑based dosing bands.

    • Provide patient weight for pediatric weight bands (e.g., 15–<30 kg, 30–<60 kg) to determine loading and maintenance doses.
    • Specify the indication to match label‑specific dosing.
    Billing Rule

    Prior authorization and coding — applies to dupilumab and unclassified biologic codes

    Include the HCPCS/J codes being billed with the prior authorization; the policy applies to dupilumab and related unclassified biologic drug codes (e.g., C9399, J3590), but listing a code does not guarantee coverage.

    • C9399 and J3590 are referenced for unclassified/biologic drugs.
    • Code inclusion is informational and does not ensure payment — follow professional coding guidance.
    Step Therapy

    Step therapy/failure requirements — prior failures of specified standard therapies

    Many indications require documented failure of specified standard therapies before dupilumab will be authorized (e.g., topical non‑steroidal therapy and medium‑to‑very high potency topical corticosteroid for atopic dermatitis; ≥2 intranasal corticosteroids for CRSwNP; PPI or corticosteroid for EoE; antihistamines and LTRA for CSU; corticosteroid plus non‑steroidal immunosuppressant for BP).

    • Atopic dermatitis: failure of one non‑steroidal topical therapy ≥4 weeks and one medium‑to‑very high potency topical corticosteroid ≥2 weeks.
    • CRSwNP: failure of ≥2 intranasal corticosteroids (one Xhance in adults) each ≥4 weeks.
    • EoE: failure of a proton pump inhibitor or corticosteroid unless contraindicated.
    Note

    Therapeutic alternatives — preferred alternatives and step options

    Preferred therapeutic alternatives and step options are listed in Appendix B and should be tried or documented as contraindicated before dupilumab (examples include topical corticosteroids and calcineurin inhibitors for AD; inhaled corticosteroid/LABA for asthma; intranasal corticosteroids for CRSwNP; systemic immunosuppressants for BP).

    • Appendix B lists specific topical corticosteroids and other preferred alternatives.
    • Asthma: ensure adherence to controller therapy (e.g., medium‑ to high‑dose ICS plus LABA) per guideline context before biologic consideration.
    Note

    Clinical guidance context — asthma and CSU references (GINA, omalizumab placement)

    Clinical guideline context is provided for asthma and CSU. GINA recommends considering dupilumab as adjunct therapy for patients ≥6 years with severe/difficult‑to‑treat asthma despite high‑dose ICS/LABA and eosinophilic biomarkers; CSU guidance references omalizumab placement in stepwise algorithms.

    • Refer to GINA for severe asthma placement and requirement for prior high‑dose ICS/LABA.
    • CSU guidance notes omalizumab as a later‑line option in stepwise care; dupilumab is not yet in guideline algorithms for CSU but trial data exist.
    Step Therapy

    Step therapy adjustment for Atopic Dermatitis — topical agent step requirement changed

    The adaptation changed the topical agent step requirement for atopic dermatitis from a triple‑step to a double‑step redirection and added immunologists to the list of prescriber options; providers should follow the revised step documentation when requesting PA.

    • Policy adaptation: topical agent requirement simplified to a double‑step (per adaptation notes).
    • Immunologist added as an acceptable prescriber for AD.
    Documentation Required

    Documentation submission requirements — chart notes, labs, pathology reports

    Submit office chart notes, relevant lab results (e.g., blood eosinophil counts), endoscopic biopsy reports (EoE eos/hpf), and pathology or serology (BP anti‑BP180/230 ELISA or immunofluorescence) to support the request.

    • EoE: biopsy showing ≥15 eosinophils per high‑power field.
    • BP: histology, serology (anti‑BP180/anti‑BP230 by ELISA), or immunofluorescence.
    • Asthma/COPD: recent blood eosinophil count (examples: asthma ≥150 cells/mcL; COPD ≥300 cells/µL).
    Documentation Required

    Off‑label supporting documentation — immunotherapy‑related pruritus

    For immunotherapy‑related pruritus (off‑label) requests, prescribers must submit supporting evidence (practice guidelines or peer‑reviewed literature) when dosing exceeds FDA‑approved regimens or for off‑label justification.

    • Prescriber must provide guideline or peer‑reviewed literature support if dose is beyond FDA maximum for any approved indication.
    • Regimen must be FDA‑approved or NCCN‑recommended for the off‑label use.
    Documentation Required

    Reference to prescribing information and FDA label as supporting materials

    Prescribing information and the FDA label are cited as supporting materials; include relevant sections of the Dupixent Prescribing Information to substantiate dosing and indication claims.

    • Reference Dupixent Prescribing Information (Regeneron) and the FDA label when submitting dosing rationale.
    • Label contains age‑ and weight‑based dosing bands and maximum dose references.
    Note

    Policy development and documentation note — adaptation history and operational changes

    The policy includes adaptation and operational history notes (e.g., step changes, added indications) from the source policy. Providers should be aware these changes when preparing documentation and PA requests.

    • RT4 updates added CSU and BP indications and revised COPD FEV1 threshold to 20–80%.
    • Operational notes document adaptation from prior policy CP PHAR.336 and prescriber/step changes.
    Denial Risk

    Denial risk for incomplete requests — missing required documentation

    Requests that do not include documentation showing the member meets all listed approval criteria (diagnosis confirmation, prior treatment failures, age/weight, prescriber specialty, dosing limits) may be denied.

    • Missing confirmation of diagnosis, required prior therapies, age/weight bands, or prescriber specialty increases denial risk.
    • Failure to document absence of concurrent biologic or JAK inhibitor therapy can result in denial.
    Denial Risk

    Denied Indications — acute bronchospasm/status asthmaticus and other exclusions

    Dupilumab is not authorized for acute bronchospasm or status asthmaticus; non‑FDA approved indications not addressed in this policy are not authorized unless sufficient off‑label evidence is submitted per off‑label policy.

    • Acute bronchospasm/status asthmaticus is an excluded indication.
    • Non‑FDA uses require evidence per CP.CPA.09 or may be denied.
    Denial Risk

    Contraindication denial risk — known hypersensitivity to Dupixent or excipients

    Known hypersensitivity to Dupixent or any of its excipients is a contraindication and will trigger denial of therapy; verify allergy/hypersensitivity status in submitted documentation.

    • Document absence of known hypersensitivity to Dupixent or its excipients.
    • Appendix C lists this as a formal contraindication.
    Billing Rule

    Coding and coverage caveat — code inclusion does not guarantee coverage

    Codes included in the policy (e.g., C9399, J3590) are informational only; inclusion or exclusion of any code does not guarantee coverage — providers must use up‑to‑date professional coding guidance when submitting claims.

    • C9399 and J3590 are cited as unclassified/biologic drug codes.
    • Providers must reference current professional coding resources for claim submission.

    Background and Clinical Context

    Dupilumab (Dupixent) is an interleukin‑4 receptor alpha antagonist targeting type‑2 inflammation and is indicated for multiple type‑2 inflammatory conditions including atopic dermatitis, asthma with an eosinophilic phenotype, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, chronic spontaneous urticaria (CSU), COPD with an eosinophilic phenotype, and bullous pemphigoid. Coverage and prior authorization criteria in this policy align with FDA‑labeled indications and require indication‑specific diagnostic confirmation, specialist prescriber involvement, prior therapy failure where applicable, and adherence to the age/weight‑based dosing limits referenced in the dosing section.

    Clinical Definitions and Diagnostic Thresholds

    EoE diagnostic threshold
    EoE diagnostic thresholdEosinophilic esophagitis is confirmed by ≥15 intraepithelial eosinophils per high‑power field (eos/hpf) on endoscopic biopsy
    Prurigo Nodularis (PN) — definition and policy context
    Definition/clinical contextPrurigo nodularis (PN): chronic pruritic disorder characterized by multiple nodular lesions; policy requires documentation (e.g., PP‑NRS/WI‑NRS score and lesion count) and dermatology involvement for coverage
    Age requirementPolicy specifies PN initial approval age ≥18 years
    Severity documentationNumeric rating scale ≥7 (0–10) and ≥20 nodular lesions across specified body areas required per coverage criteria
    Chronic Spontaneous Urticaria (CSU) — definition and policy context
    Definition/clinical contextChronic Spontaneous Urticaria (CSU): spontaneous wheals, angioedema, or both for >6 weeks with unknown cause; policy requires specialist involvement and prior antihistamine/LTRA trials
    Age requirement and dosing notePolicy allows CSU initiation at age ≥12 years with age/weight‑stratified dosing (e.g., age 12–17 weight 30–<60 kg: 200 mg Q2W; ≥60 kg: 300 mg Q2W)
    Prior therapy requiredFailure of two antihistamines (one second‑generation) at max doses for ≥2 weeks and failure of an LTRA plus antihistamine at max doses for 2 weeks required before approval
    CRSwNP — definition, management context and guideline references
    Definition/clinical contextChronic rhinosinusitis with nasal polyposis (CRSwNP): chronic rhinosinusitis with documented nasal polyps and bilateral disease ≥12 weeks; specialist (ENT, allergist) involvement and prior intranasal corticosteroid trials required
    Treatment contextDupilumab prescribed concurrently with an intranasal corticosteroid unless contraindicated; prior requirement of systemic corticosteroids within last 2 years (unless contraindicated)
    Guideline/consensus referencesPolicy references multidisciplinary consensus and stepwise treatment algorithms for CRSwNP (see Peters AT et al., EUFOREA and Han JK et al.)
    Patient‑reported itch scales (PP‑NRS / WI‑NRS)
    Scale descriptionPP‑NRS and WI‑NRS are single‑item patient‑reported numeric rating scales assessing peak/worst itch in the prior 24 hours on a 0 (no itch) to 10 (worst imaginable) scale
    Use in policyPolicy uses these scales to document symptom severity (e.g., PN requires PP‑NRS/WI‑NRS ≥7)
    NCCN pruritus and bullous dermatitis grading
    NCCN pruritus grading summaryGrades for immunotherapy‑related pruritus: G1 mild/localized; G2 moderate (intense/widespread, intermittent, limiting instrumental ADLs); G3 severe (intense/widespread, constant, limiting self‑care ADLs or sleep)
    NCCN bullous dermatitis gradingBullous dermatitis grades include G1 (asymptomatic; blisters covering ≤10% BSA) through G3 (blisters covering ≥30% BSA and limiting self‑care ADLs); highest grades may require ICU-level care
    EoE diagnostic criteria referenced
    Core diagnostic criteria referencedPolicy references updated international consensus diagnostic criteria for EoE (e.g., Dellon et al., 2018) and requires histologic confirmation of ≥15 eos/hpf on biopsy
    Exclusion considerationsMember must not have hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis to meet EoE criteria
    Required specialist involvement and weight limitsEoE coverage requires prescription by or consultation with allergist, immunologist, or gastroenterologist and weight ≥15 kg (age ≥1 year) per policy
    CRSwNP management consensus and stepwise treatment algorithm
    Consensus management referencePolicy cites multidisciplinary consensus and stepwise algorithms for CRSwNP management (e.g., EUFOREA, Han et al. Int Forum Allergy Rhinol. 2021)
    Stepwise treatment elementsPolicy expects prior failure of maintenance therapy with ≥2 intranasal corticosteroids (one may be Xhance in adults) each used ≥4 weeks unless contraindicated before biologic therapy
    Guideline integrationReferences include practice parameters and multidisciplinary consensus to support stepwise use of biologics in CRSwNP

    Policy Update History

    2025-06-25indication_added

    Bullous pemphigoid (BP) added as a covered indication per updated prescribing information and P&T-approved clinical guidance.

    2025-06-09threshold_revised

    COPD post-bronchodilator FEV1 requirement revised from 30-70% to 20-80% predicted to align with related biologic criteria.

    2025-06-09indication_addedLatest

    Chronic spontaneous urticaria (CSU) added as a covered indication per updated prescribing information.